Alembic Pharmaceuticals reported a strong Q1 FY27 with consolidated revenue up 26% year-on-year to ₹2,150 crore. The company also raised its revenue growth outlook for FY27 to mid-teens, driven by its US Generics and API businesses.
Alembic Pharmaceuticals Q1 FY27 Results
Consolidated Revenue: ₹2,150 crore (26% YoY growth) Reported EBITDA: ₹348 crore (21% YoY growth) Reader Takeaway: Strong revenue growth driven by US Generics and API; debt levels require monitoring. ## What just happened Alembic Pharmaceuticals has posted a robust Q1 FY27 performance, with consolidated revenue climbing 26% year-on-year to ₹2,150 crore. Earnings before interest, taxes, depreciation, and amortization (EBITDA) also saw a healthy 21% increase to ₹348 crore, resulting in an EBITDA margin of 16%. The company's Profit After Tax (PAT) grew 12% to ₹173 crore. ## Why this matters The significant revenue growth, particularly in key segments like US Generics and API, indicates strong operational execution. The company's decision to raise its revenue growth forecast for FY27 to mid-teens signals management's confidence in sustained performance. However, an increase in gross debt to ₹1,600 crore, attributed to working capital needs, warrants investor attention. ## The backstory Alembic Pharmaceuticals has been focusing on expanding its international generics business, especially in the US, alongside its Active Pharmaceutical Ingredients (API) segment. The Animal Health division has also been a consistent growth driver. The company has been strategically investing in R&D for future pipeline development. ## What changes now With the upward revision in its FY27 revenue growth outlook, Alembic Pharma signals an optimistic trajectory. The company plans to focus on the chronic portfolio and specialty therapies in its Human Health segment under new leadership. Management expects its working capital situation to improve in coming quarters, aiming to bring debt levels back to a sustainable ratio. ## Risks to watch Increased solvent costs and planned investments in the US branded platform have impacted EBITDA margins, causing a 150 bps dilution. The rise in gross debt, though attributed to receivables from higher sales, needs to be monitored for unwinding. The strategic execution in the Human Health segment under new leadership is also a key area to watch. ## Peer comparison While specific peer comparisons are not detailed in the filing, Alembic Pharma's growth in US Generics and API segments aligns with broader industry trends of companies leveraging international markets for revenue diversification and growth. The 26% YoY revenue growth is a strong indicator in the current market. ## Context metrics (time-bound) * Consolidated Revenue for Q1 FY27: ₹2,150 crore (up 26% YoY). * EBITDA for Q1 FY27: ₹348 crore (up 21% YoY). * PAT for Q1 FY27: ₹173 crore (up 12% YoY). * R&D Expenditure for the quarter: ₹186 crore (approx. 9% of revenue). * Gross Debt as of June 2026: ₹1,600 crore. ## What to track next Investors will be keen to observe the normalization of working capital and subsequent reduction in debt levels. The performance of the US Generics segment, new product launches, and the turnaround strategy for the India Human Health business will be crucial indicators for future growth.
